Beijing KEY-BIO Biotech Co.,Ltd. (hereinafter referred to as "KEY-BIO") was established in 2007 and is a supplier and service provider specializing in the systematic research of active raw materials for in vitro diagnostic reagents. The company currently has a research and development base located in Fengtai District, Beijing and a production demonstration base located in Daxing District, Beijing, with a total area of 6,400 square meters. The company has been recognized as a national high-tech enterprise since 2016. In 2017, it passed the ISO9001 Quality Management System certification. It has successively passed the ISO14001 Environmental Management System certification, ISO45001 occupational Health Management System certification, and GB/T29490-2023 Intellectual Property Management System certification. ISO56005 Innovation and Intellectual Property Management Capability Certification Recognized as a "dual-independent enterprise" by the Beijing Municipal Commission of Commerce, it was successively rated as a Beijing Specialized, Refined, Unique and Innovative "Little Giant" enterprise and a national Specialized, refined, unique and innovative "Little Giant" enterprise in 2022. It was also selected as one of the top 100 small and medium-sized private enterprises in Beijing in 2022 and was consecutively included in the top 100 specialized, refined, unique and innovative enterprises in Beijing in 2023 and 2024. It was selected as one of the top 100 high-growth enterprises in Zhongguancun for three consecutive years from 2021 to 2023. It was awarded the Certificate of Beijing Enterprise Innovation Credit Leading Enterprise in 2022, 2023 and 2024. In 2023, it won the "16th National Commercial Quality Award" and the "Third Prize" of the National Service Industry Science and Technology Innovation Award. In 2024, it won the "Outstanding Award" at the 18th Beijing Invention and Innovation Competition. In 2024, it was rated as a high-tech enterprise with an innovation capability evaluation grade of "AAAAA", and was selected as a supported unit for the layout of invention patents among technology-based small and medium-sized enterprises and a pilot unit for intellectual property rights in Beijing. The company currently holds 33 authorized invention patents, 1 utility model patent, has obtained 18 registered trademarks, and drafted 3 group standards that have been released. There are over 20 ongoing research projects, and it has been rated as an "A-level Tax Credit Enterprise" for more than 10 consecutive years.

KEY-BIO products mainly include raw materials for antigens, antibodies and markers used in the detection of infectious diseases, sex hormones, thyroid hormones, tumor markers, cytokines, heart and kidney functions, etc. The products have been widely and maturely applied in platforms such as ELISA, plate chemiluminescence, magnetic particle -ALP chemiluminescence, magnetic particle - acridine esterification chemical luminescence, immunochromatography, microfluidics, and biochemical turbidimetry. Based on the absorption of advanced technologies and processes both at home and abroad, and drawing on years of practical experience, KEY-BIO continuously develops new and high-quality products, aiming to provide the driving force for research in the field of human life sciences.

KEY-BIO now possesses technical platforms such as genetic engineering, protein engineering, antibody engineering, and labeled immunoassay. By leveraging sufficient technical strength and complete R&D and production equipment, it systematically conducts research and development on bioactive raw materials, intermediates, and reagents.

KEY-BIO adheres to the concept of "facilitating technological leaps and becoming a model in China". On the basis of persisting in technological innovation, it strictly controls quality management and continuously improves technical levels, achieving the healthy development of the company's business. Nowadays, the marketing network of Zhongkai Biological products not only covers the whole country but also is exported to the international market.

In the future, KEY-BIO will continue to shoulder the mission of "devoting to the cause of human health", bravely explore life sciences, empower the health industry with technology, and enable more scientific and technological progress and innovative achievements to serve human health.